The optimized solution offered by Agilent and Biotek integrates the Agilent Seahorse XFe96/XFe24 Analyzers with the Biotek Cytation 1 Cell Imaging Multi-Mode Reader
(Source: Agilent)
Santa Clara/USA — The optimized solution integrates the Agilent Seahorse XFe96/XFe24 Analyzers with the Biotek Cytation 1 Cell Imaging Multi-Mode Reader. This solution creates a standardized approach for comparing XF data sets, improving assay workflow, embedding images into Wave software, and applying normalization values to Seahorse XF measurements, the companies announced.
According to Gary Barush, Global Director of Marketing and Sales at Biotek, the new approach created a distinct opportunity for cell biology researchers to fully normalize and analyze samples to answer challenging questions regarding cellular metabolism. David Ferrick, Ph.D., Senior Director of Agilent's Cell Analysis Division, added that customers benefit from an optimized method for verifying assay results, and enabling more meaningful data comparisons provided by the data-rich assays. This integrated solution gave their customers the ability to compare XF data on a well-to-well, plate-to-plate, and experiment-to-experiment basis.
The new solution allows researchers to toggle between XF data, brightfield images, and fluorescence images in a unified software experience. Referencing the images while analyzing XF data provides evidence and guidance on how to limit variability and improve the reproducibility of their XF assays. Applying a cell count based normalization value ultimately makes interpreting Seahorse XF data and finding relationships amongst the data easier.
The partners will jointly market the integrated solution, planned for release in the US and Europe in April 2018, and the rest of the world by June 2018.
Unfold for details of your consent
Stand vom 23.03.2021
Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.
Consent to the use of data for promotional purposes
I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here
Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.
In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.
Right of revocation
I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.